A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. - Wikidata - awgldk - TriplyDB

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

http://www.wikidata.org/entity/Q33343973

about

Treatment including intrathecal chemotherapy with and without cranial irradiation for prevention of central nervous system relapse of childhood acute lymphoblastic leukemia Treatment including intrathecal chemotherapy with and without cranial irradiation for prevention of central nervous system relapse of childhood acute lymphoblastic leukemia AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL The Philadelphia chromosome in leukemogenesis Imatinib in chronic myeloid leukemia: an overview Clonal evolution in hematological malignancies and therapeutic implications Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.Chronic myelogenous leukemia: treatment and monitoring.Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia Evaluating the predictivity of virtual screening for ABL kinase inhibitors to hinder drug resistance Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Cancer treatment with kinase inhibitors: what have we learnt from imatinib?Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia.Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.A closer look at specific therapeutic strategies in leukemia.A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.Favorable outcome of allogeneic hematopoietic stem cell transplantation followed by post-transplant treatment with imatinib in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells.Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients.Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study Emerging drugs for adult acute lymphoblastic leukaemia.

P2860

Q24197564-2E833BC0-F6A8-499A-8987-20831A8250E9 Q24236240-212EBEE2-AE4F-449A-B237-109496D7F247 Q24651465-FA76F5DB-D181-4087-8CB6-026F3776F472 Q26745531-9B926DD6-14CA-49C9-8B95-D98DC5E9643A Q26865086-997ED11C-15E4-4DDC-9541-9486812E7985 Q27027655-79CD5530-8B3A-40FC-A476-EC6FDB9CE727 Q27660281-4C584E75-8D6D-46DA-B99B-A399378DD9A3 Q27852657-E5BC3E83-457D-4A19-A97E-3A647C4FB28E Q28473957-92B59485-74CD-493D-B080-A3780AF4A240 Q33822004-AAE36282-B842-4E63-B469-5F3F4FA03FE2 Q33915980-E0D06376-F5B1-4D58-BB57-046C0E9BA595 Q33996893-F14E4426-4FC0-47E8-8D2D-77458BF0B7CA Q34052899-80AE7E7C-2500-4143-99E9-C569EEBF9113 Q34350665-FFDBB0F9-B4CB-40E0-B0AC-E9B7595F418C Q34378360-E4CE7D00-6B37-4DA7-B356-462EDE81E945 Q34557165-1C5DB8FA-FC5C-48A8-A3CF-6EC0134A1D60 Q34617628-CFAA1583-495A-4737-9508-6AE45E8C86D3 Q34644820-9AF5D69E-F79F-45C5-97B7-172E0397B9FF Q34762595-B85869E2-EB89-4E6F-B87C-F899491FCB86 Q35022505-DC9E634A-34F7-4CAF-AE78-DCB6052E42AE Q35102183-7DCD3FB9-C99D-4507-990A-3948D45B07CC Q35128883-79AF0E87-A9D8-443B-891C-74C43DE1BAFE Q35171267-050DE52B-3912-4397-A37F-D738B9BB1482 Q35571035-4786A175-7E39-48DE-8E7C-BE40E0454264 Q35622440-DCF602C0-B702-4645-A94C-9B73C3A19916 Q35642790-04B61315-5733-4171-9400-D621A51FC512 Q35750934-92A594BF-F0B0-48DC-A513-4D8EE70C0213 Q35751017-A30E0A88-3B32-491F-82BE-C5A10D7AB68F Q35782565-E80A98EF-8EA2-4E30-BB57-6062A097F7EE Q35816396-2187358E-1386-471D-98B3-E1D56522B66D Q35821017-397DEAE2-4EAB-4FC1-B5EE-F1168CEECB5E Q35865095-980FE254-41D6-4A4A-9892-08796563E485 Q35945171-7D5807D2-24B0-47C8-BBDE-E7B80F121FC5 Q35967452-73B9A708-AD79-4E34-A29F-2AF2E7C44C73 Q36040272-1C48C926-EE3F-4DEA-B5E2-E4F460F9A761 Q36128159-320577EF-E2FC-4347-94FF-CF2F059B0D7A Q36164524-38FA3C40-07CF-4742-A3F2-256AFFE797E9 Q36194683-D071C274-6920-4E33-AB3D-5163AFAC4F3A Q36201257-2C707F0F-09C9-4F9C-AC51-AC98FB09AD11 Q36219661-25F9BBEB-89E7-447C-AEB1-F8F4B6EEA436

P2860

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

http://www.wikidata.org/entity/Q33343973

description

2002 nî lūn-bûn

@nan

2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

A phase 2 study of imatinib in ...... tive acute lymphoid leukemias.

@ast

A phase 2 study of imatinib in ...... tive acute lymphoid leukemias.

@en

type

label

A phase 2 study of imatinib in ...... tive acute lymphoid leukemias.

@ast

A phase 2 study of imatinib in ...... tive acute lymphoid leukemias.

@en

prefLabel

A phase 2 study of imatinib in ...... tive acute lymphoid leukemias.

@ast

A phase 2 study of imatinib in ...... tive acute lymphoid leukemias.

@en

P1433

Q33343973-CCA5ED00-B26E-4A53-A860-97ED03949F4D

P1476

Q33343973-E8E486FE-A17A-4388-98FA-3173AD5224E6

P2093

Q33343973-0B7FD130-FEEF-4F2D-8734-9F5465FF4E0E

Q33343973-177E7C0F-D6D4-4EDB-978F-125FD5F867C9

Q33343973-1810886F-ABF5-4561-B274-EA2C9DA69A13

Q33343973-1F09983C-C2C2-4F8C-8E7A-AD2441E1F9B0

Q33343973-3625FAFD-2C75-49E9-AF50-1BF6CAAD1546

Q33343973-4BAB034B-FFF1-45F1-ACEE-596016871F01

Q33343973-51FE6CA9-2101-4D95-A36A-B212343CB90A

Q33343973-5C764FBD-0853-43D7-8DED-1F400F28A32B

Q33343973-AF4ABC5C-C832-4126-8A45-83E06FFC05C3

Q33343973-D2696A21-447E-422E-865A-F643EA54C79F

P304

Q33343973-FCFE92EA-981F-41B0-84C2-EBECE1FC9651

P31

Q33343973-83BB00AC-ADE9-4C4A-B3D9-D0FED900ADA7

P356

Q33343973-4C9628BA-7B57-48E0-9D21-3A5596B4CCEE

P407

Q33343973-3EC45047-7CE6-4F79-B286-9F180C71CCF5

P433

Q33343973-83A4DD62-977E-4308-8673-4FA618858B0C

P478

Q33343973-FE666842-DF13-45DF-82A6-C7E9B1598285

P50

Q33343973-0A24B282-9923-402F-81F2-872720EC2FBD

Q33343973-21C7E0CD-5E11-4660-B190-7C7D7313B069

Q33343973-4DB91909-3D08-41C4-A778-21BA30D9A10E

Q33343973-E3E4990D-B58E-43ED-BA28-733AA5605CCA

Q33343973-EB7B05DE-B14A-471E-8A2B-297F7230C3A7

P577

Q33343973-48BC2C22-785D-4035-898D-F7140CEA7559

P5875

Q33343973-26E48F35-F537-4BA7-8BCF-649AE819D97A

P698

Q33343973-42BD5DBC-4A03-445F-8660-0E37BA7E959A

P921

Q33343973-D6551005-3337-4AB9-B610-0FF7C606BAB5

P356

BLOOD-2001-12-0181

P1433

P1476

A phase 2 study of imatinib in ...... tive acute lymphoid leukemias.

@en

P2093

Charles A Schiffer

http://www.w3.org/2001/XMLSchema#string

Charles L Sawyers

http://www.w3.org/2001/XMLSchema#string

Dieter Hoelzer

http://www.w3.org/2001/XMLSchema#string

Insa Gathmann

http://www.w3.org/2001/XMLSchema#string

John M Goldman

http://www.w3.org/2001/XMLSchema#string

Jose Reiffers

http://www.w3.org/2001/XMLSchema#string

Michael W Deininger

http://www.w3.org/2001/XMLSchema#string

Renaud Capdeville

http://www.w3.org/2001/XMLSchema#string

Richard T Silver

http://www.w3.org/2001/XMLSchema#string

Sante Tura

http://www.w3.org/2001/XMLSchema#string

P304

1965-1971

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2001-12-0181

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Hochhaus

Brian J. Druker

Michele Baccarani

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11188778

http://www.w3.org/2001/XMLSchema#string

P698

12200353

http://www.w3.org/2001/XMLSchema#string

P921